RenovoRx (RNXT) investor relations material

Company overview and business model

• Develops targeted oncology therapies and commercializes RenovoCath, an FDA-cleared local drug-delivery device for cancer treatment.

• Focuses on the Trans-Arterial Micro-Perfusion (TAMP) therapy platform for intra-arterial delivery of therapeutics to tumors, aiming to improve efficacy and reduce toxicity.

• Commercial-stage growth company with first commercial sales of RenovoCath in December 2024 and $1.1 million in revenue for 2025.

• Expanding adoption in U.S. cancer centers, with 12 centers using RenovoCath and 21 more evaluating or preparing for activation as of February 2026.

• Ongoing Phase III TIGER-PaC trial for a drug-device combination (IAG) using RenovoCath and gemcitabine, with orphan drug designation for pancreatic and bile duct cancer.

Financial performance and metrics

• Generated $1.1 million in revenue from RenovoCath sales in 2025, with repeat and new orders from U.S. cancer centers.

• Raised approximately $10 million in gross proceeds from a March 2026 private placement.

• Common stock traded on Nasdaq Capital Market under symbol "RNXT"; last reported price was $1.02 per share on April 15, 2026.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling stockholders; may receive up to $9.3 million from exercise of Milestone Warrants if exercised for cash.

• Proceeds from warrant exercises intended for general corporate purposes, including working capital, and potentially for acquisitions or investments in complementary products or technologies.